Merz Pharms Gmbh Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MERZ PHARMS GMBH, and what generic alternatives to MERZ PHARMS GMBH drugs are available?
MERZ PHARMS GMBH has two approved drugs.
There are six US patents protecting MERZ PHARMS GMBH drugs.
There are ninety-one patent family members on MERZ PHARMS GMBH drugs in twenty-two countries and two supplementary protection certificates in two countries.
Summary for Merz Pharms Gmbh
International Patents: | 91 |
US Patents: | 6 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Merz Pharms Gmbh
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,685,442 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,545,878 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 9,393,210 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 7,182,961 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | RE43711 | ⤷ Sign Up | ⤷ Sign Up | ||||
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | 8,945,612 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Merz Pharms Gmbh | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Merz Pharms Gmbh
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 6,514,482 | ⤷ Sign Up |
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 8,404,276 | ⤷ Sign Up |
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 9,155,699 | ⤷ Sign Up |
Merz Pharms Gmbh | AMPYRA | dalfampridine | TABLET, EXTENDED RELEASE;ORAL | 022250-001 | Jan 22, 2010 | 5,540,938 | ⤷ Sign Up |
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 7,182,961 | ⤷ Sign Up |
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 8,628,754 | ⤷ Sign Up |
Merz Pharms Gmbh | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | 6,979,437 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MERZ PHARMS GMBH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Tablets | 10 mg | ➤ Subscribe | 2014-01-22 |
International Patents for Merz Pharms Gmbh Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | 112015010603 | ⤷ Sign Up |
South Korea | 20230116102 | ⤷ Sign Up |
New Zealand | 708684 | ⤷ Sign Up |
Australia | 2013342248 | ⤷ Sign Up |
Japan | 6836834 | ⤷ Sign Up |
Canada | 2890459 | ⤷ Sign Up |
Japan | 6348501 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Merz Pharms Gmbh Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | CR 2015 00042 | Denmark | ⤷ Sign Up | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
1613296 | 92782 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.